Strain-dependent susceptibility to MPTP and MPP+-induced parkinsonism is determined by glia

GLIA

Volumn 34, Issue 2, 2001, Pages 73-80

  Smeyne, Michelle ^a   Goloubeva, Olga ^a   Smeyne, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cell culture; Dopamine; Parkinson's disease; Reactive oxygen species

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HERBICIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CELL DEATH; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; GLIA; METABOLISM; MOUSE; PARKINSONISM; PATHOLOGY; SPECIES DIFFERENCE; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELL DEATH; CELLS, CULTURED; DOPAMINE; DOPAMINE AGENTS; HERBICIDES; MICE; MICE, INBRED C57BL; NEUROGLIA; PARKINSONIAN DISORDERS; REACTIVE OXYGEN SPECIES; SPECIES SPECIFICITY; SUBSTANTIA NIGRA;

EID: 0035870598     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.1042     Document Type: Article

References (74)

1. Ali SF, David SN, Newport GD, Cadet JL, Slikker W Jr. 1994. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18:27-34.
2. Baker H, Joh TH, Reis DJ. 1980. Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: relationship to size and neuronal density of the striatum. Proc Natl Acad Sci USA 77:4369-4373.
3. Bayer SA, Wills KV, Triarhou LC, Ghetti B. 1995. Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp Brain Res 105:191-199.
4. Brenneman DE, Phillips TM, Festoff BW, Gozes I. 1997. Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Ann NY Acad Sci 814:167-173.
5. Bronstein DM, Perez-Otano I, Sun V, Mullis Sawin SB, Chan J, Wu GC, Hudson PM, Kong LY, Hong JS, McMillian MK. 1995. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 704:112-116.
6. +. J Neural Transm 76:1-12.
7. Cardozo DL. 1993. Midbrain dopaminergic neurons from postnatal rat in long-term primary culture. Neuroscience 56:409-421.
8. - opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453:49-62.
9. Checkoway H, Nelson LM. 1999. Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10:327-336.
10. Chiueh CC, Wu RM, Mohanakumar KP, Sternberger LM, Krishna G, Obata T, Murphy DL. 1994. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann NY Acad Sci 738:25-36.
11. Cunningham M, McKay R. 1994. Transplantation strategies for the analysis of brain development and repair. J Neurol 242:S40-42.
12. +) cytotoxicity. Biochem Biophys Res Commun 137:303-309.
13. Di Monte DA, Royland JE, Irwin I, Langston JW. 1996. Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology 17:697-703.
14. Dringen R, Pfeiffer B, Hamprecht B. 1999. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19:562-569.
15. Drukarch B, Schepens E, Stoof JC, Langeveld CH, Van Muiswinkel FL. 1998. Astrocyte-enhanced neuronal survival is mediated by scavenging of extracellular reactive oxygen species. Free Rad Biol Med 25:217-220.
16. Ferrante RJ, Hantraye P, Brouillet E, Beal MF. 1999. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res 823:177-182.
17. 2+ release from mitochondria. FEBS Lett 198:99-102.
18. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. 1997. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325.
19. Gerlach M, Riederer P, Przuntek H, Youdim MB. 1991. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208:273-286
20. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK. 1996. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5:299-312.
21. Glover V, Gibb C, Sandler M. 1986. The role of MAO in MPTP toxicity - a review. J Neural Transm 20(suppl):65-76.
22. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ. 1999. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828:91-103.
23. Han J, Cheng FC, Yang Z, Dryhurst G. 1999. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J Neurochem 73:1683-1695.
24. Hastings TG, Zigmond MJ. 1997. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J Neural Transm 49(suppl):103-110.
25. Hatakeyama S, Hayasaki Y, Masuda M, Kazusaka A, Fujita S. 1996. Mechanism for mouse strain differences in the protective effect of Sudan III against the in vivo genotoxicity of 7,12-dimethylbenz [a]anthracene. Toxicol Lett 89:231-239.
26. Hazell AS, Itzhak Y, Liu H, Norenberg MD. 1997. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem 68:2216-2219.
27. Higuchi S, Muramatsu T, Arai H, Hayashida M, Sasaki H, Trojanowski JQ. 1995. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transm 10:107-113.
28. Hirsch EC, Hunot S. 2000. Nitric oxide, glial cells and neuronal degeneration in parkinsonism. TIPS 21:163-165.
29. Hirsch EC, Hunot S, Damier P, Faucheux B. 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 44:S115-120.
30. Hirsch EC, Hunot S, Damier P, Faucheux B. 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 44:S115-120.
31. Hou JG, Cohen G, Mytilineou C. 1997. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hy-droxydopamine toxicity: involvement of the glutathione system. J Neurochem 69:76-83.
32. + toxicity: role of BDNF gene expression. Mol Brain Res 41:14-26.
33. Ibi M, Sawada H, Kume T, Katsuki H, Kaneko S, Shimohama S, Akaike A. 1999. Depletion of intracellular glutathione increases susceptibility to nitric oxide in mesencephalic dopaminergic neurons. J Neurochem 73:1696-1703.
34. Jellinger KA. 1996. Structural basis of dementia in neurodegenerative disorders. J Neural Transm 47(suppl):1-29.
35. Jenner P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Dis 13(suppl 1):24-34.
36. Jenner P, Marsden CD. 1993. MPTP-induced Parkinsonism: a model of Parkinson's disease and its relevance to the disease process. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins. p 55-75.
37. Johannessen JN, Chiueh CC, Bacon JP, Garrick NA, Burns RS, Weise VK, Kopin IJ, Parisi JE, Markey SP. 1989. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment. J Neurochem 53:582-589.
38. Kondo D, Kurland LT, Schull WJ. 1973. Parkinson's disease. Genetic analysis and evidence of a multifactorial etiology. Mayo Clin Proc 48:465-475.
39. Kopin IJ. 1992. Features of the dopaminergic neurotoxin MPTP. Ann NY Acad Sci 648:96-104.
40. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, Snow B, Olanow CW. 1998. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 13:383-393.
41. Kordower JH, Goetz CG, Freeman TB, Olanow CW. 1997. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol 144:41-46.
42. Kuhn DM, Aretha CW, Geddes TJ. 1999. Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. J Neurosci 19:10289-10294.
43. Leighton PW, Le Couteur DG, Pang CC, McCann SJ, Chan D, Law LK, Kay R, Pond SM, Woo J. 1997. The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology 49: 1577-1579.
44. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Med 5:1403-1409.
45. Lieb K, Andersen C, Lazarov N, Zienecker R, Urban I, Reisert I, Pilgrim C. 1996. Pre- and postnatal development of dopaminergic neuron numbers in the male and female mouse midbrain. Dev Brain Res 94:37-43.
46. Maines MD. 1988. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2:2557-2568.
47. Mari Z, Bodis-Wollner I. 1997. MPTP-induced Parkinsonian syndrome in humans and animals: how good is the model? In: Beal MF, Howell N, Bodis-Wollner I, editors. Mitochondria and free radicals in neurodegenerative diseases. New York: Wiley-Liss. p 189-228.
48. Marsden CD, Jenner PG. 1987. The significance of 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine. Ciba Found Symp 126:239-256.
49. McGeer PL, McGeer EG. 1998. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Dis 12(suppl 2):S1-6.
50. McNaught KSP, Jenner P. 1999. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 73:2469-2476.
51. Mercier G, Turpin JC, Lucotte G. 1999. Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: no association found. J Neurol 246:45-47.
52. Michel PP, Vyas S, Agid Y. 1992. Toxic effects of iron for cultured mesencephalic dopaminergic neurons derived from rat embryonic brains. J Neurochem 59:118-127.
53. Milliken GA. 1992. Analysis of messy data. Vol I: Design of experiments. New York: Chapman & Hall.
54. +) against mitochondria of mouse brain. J Neurol Sci 86:97-110.
55. Pifl C, Giros B, Caron MG. 1993. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13:4246-4253.
56. Prasad KN, Clarkson ED, La Rosa FG, Edwards-Prasad J, Freed CR. 1998. Efficacy of grafted immortalized dopamine neurons in an animal model of parkinsonism: a review. Mol Genet Metab 65:1-9.
57. +. Neurosci Lett 75:323-328.
58. Renkawek K, Stege GJ, Bosman GJ. 1999. Dementia, gliosis and expression of the small heat shock proteins hsp27 and alpha B-crystallin in Parkinson's disease. Neuroreport 10:2273-2276.
59. + and MPTP-analogues in biological samples after purification over Sephadex G10. Life Sci 37:1633-1640.
60. Sagara JI, Miura K, Bannai S. 1993. Maintenance of neuronal glutathione by glial cells. J Neurochem 61:1672-1676.
61. Sanchez-Ramos JR, Michel P, Weiner WJ, Hefti F. 1988. Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence. J Neurochem 50:1934-1944.
62. Schmidt J, Mertz K, Morgan JI. 1999. Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes. Mol Brain Res 73:50-59.
63. Schneider JS, Denaro FJ. 1988. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J Neuropathol Exp Neurol 47:452-458.
64. Schneider JS, Yuwiler A, Markham CH. 1987. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res 411:144-150.
65. Searle SR. 1987. Linear models for unbalanced data. New York: John Wiley & Sons.
66. Shih JC, Chen K. 1999. MAO-A and -B gene knock-out mice exhibit distinctly different behavior. Neurobiology 7:235-246.
67. Sriram K, Pai KS, Boyd MR, Ravindranath V. 1997. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res 749:44-52.
68. Stoessl AJ. 1999. Etiology of Parkinson's disease. Can J Neurol Sci 26(suppl 2):S5-12.
69. Tanaka T, Naganuma A, Kobayashi K, Imura N. 1991. An explanation for strain and sex differences in renal uptake of methylmercury in mice. Toxicology 69:317-329.
70. Wang XF, Cynader MS. 2000. Astrocytes provide cysteine to neurons by releasing glutathione. J Neurochem 74:1434-1442.
71. Womer DE, Jones BC, Erwin VG. 1994. Characterization of dopamine transporter and locomotor effects of cocaine, GBR 12909, epidepride, and SCH 23390 in C57BL and DBA mice. Pharmacol Biochem Behav 48:327-335.
72. + in vivo. Eur J Pharmacol 243:241-247.
73. Zhang J, Piantadosi CA. 1992. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest 90:1193-1199.
74. Zietlow R, Dunnett SB, Fawcett JW. 1999. The effect of microglia on embryonic dopaminergic neuronal survival in vitro: diffusible signals from neurons and glia change microglia from neurotoxic to neuroprotective. Eur J Neurosci 11:1657-1667.